Research Abstract
Clinical Trials for Breast Cancer
Jerry Younger, MD
Massachusetts General Hospital
Massachusetts General Hospital
Phone: (617) 726-8698
Fax: (617) 724-1079
Jerry Younger, MD
Massachusetts General Hospital
EDUCATIONAL TITLES
DF/HCC PROGRAM AFFILIATION
Publications
- Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clin Cancer Res 2020. PubMed
- Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop IE, Morganstern D, Sohl J, Hu J, Kasparian E, Winer EP, Lin NU. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res 2021; 22:131. PubMed
- Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR) Breast Cancer. Clin Cancer Res 2019. PubMed
- Bardia A, Iafrate JA, Sundaresan T, Younger J, Nardi V. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist 2016; 21:1035-40. PubMed
- Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013; 142:405-14. PubMed
- Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers 2013. PubMed
- Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat 2011. PubMed
- Bush D, Smith B, Younger J, Michaelson JS. The non-breast-cancer death rate among breast cancer patients. Breast Cancer Res Treat 2010. PubMed
- Chen LL, Nolan ME, Silverstein MJ, Mihm MC, Sober AJ, Tanabe KK, Smith BL, Younger J, Michaelson JS. The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer 2009; 115:5071-83. PubMed
- Michaelson JS, Chen LL, Silverstein MJ, Cheongsiatmoy JA, Mihm MC, Sober AJ, Tanabe KK, Smith BL, Younger J. Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. Cancer 2009; 115:5084-94. PubMed
- Michaelson JS, Chen LL, Silverstein MJ, Mihm MC, Sober AJ, Tanabe KK, Smith BL, Younger J. How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. Cancer 2009; 115:5095-107. PubMed
- Hesketh PJ,Younger J,Sanz-Altamira P,Hayden M,Bushey J,Trainor B,Krentzin M,Nowd P,Arnaoutakis K,Hesketh AM. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 2008. PubMed
- Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14:7871-7. PubMed
- Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112:2359-67. PubMed
- Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by Cancer Treat Rev 2008; 34:223-230. PubMed
- Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993-9. PubMed
- Younger JF, Plein S, Barth J, Ridgway JP, Ball SG, Greenwood JP. Troponin-I concentration 72 h after myocardial infarction correlates with infarct size and presence of microvascular obstruction. Heart 2007; 93:1547-51. PubMed
- Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology 2007; 16:895-903. PubMed
- Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs 2006; 25:161-4. PubMed
- Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5:607-16. PubMed
- FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334:143-9. PubMed